Tafolecimab cut LDL-C by more than 60% in 12 weeks as a standalone therapy, without a statin in sight. That number, from Innovent’s Phase 3 CREDIT-5 trial, is what makes this readout commercially interesting: the study was designed specifically to test the drug in patients who have not yet started any lipid-lowering treatment, a population the current NMPA-approved label for SINTBILO does not cover.
CREDIT-5 enrolled 198 Chinese adults with non-familial hypercholesterolemia or mixed hyperlipidemia, randomized 2:1:2:1 to tafolecimab 150 mg Q2W, matched placebo Q2W, tafolecimab 450 mg Q4W, or matched placebo Q4W. Both arms hit the primary endpoint with p-values below 0.0001. Beyond LDL-C, Lp(a) fell by nearly 50% at week 12, a secondary finding that matters because Lp(a) elevation is an independent cardiovascular risk factor that statins do not meaningfully address. The drug also cut ApoB, non-HDL-C, and vLDL-C, and no severe treatment-emergent adverse events were recorded.
The practical stakes are clearer when you consider why a first-line monotherapy label is worth pursuing. Statins remain the standard starting point for hypercholesterolemia, but some Chinese patients on statins experience adverse reactions, and long-term adherence is a persistent clinical problem. A patient who cannot tolerate statins, or who declines them, currently has limited evidence-based alternatives at initiation. CREDIT-5 generates that evidence directly. Innovent plans to file a new indication application with the NMPA shortly, and SINTBILO’s inclusion in China’s National Reimbursement Drug List since January 2025 means a reimbursed first-line option could reach a substantially larger patient pool than the current on-statin-background positioning allows.
The number to watch from here is the NMPA review timeline. SINTBILO already has the reimbursement infrastructure in place and has reached more than one million patients under its existing label; the size of the incremental opportunity depends entirely on how quickly regulators accept a monotherapy indication and whether the NRDL coverage extends to cover it.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
